BioXcel Therapeutics Inc (NASDAQ:BTAI)’s traded shares stood at 78653.0 during the last session, with the company’s beta value hitting 0.06.The BTAI share’s 52-week high remains $21.92, putting it -1035.75% down since that peak but still an impressive 39.38% since price per share fell to its 52-week low of $1.17. The company has a valuation of $11.69M, with an average of 0.41 million shares in intraday trading volume over the past 10 days and average of 262.96K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for BioXcel Therapeutics Inc (BTAI), translating to a mean rating of 1.75. Of 8 analyst(s) looking at the stock, 0 analyst(s) give BTAI a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 7 recommend it as a Buy.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
The 5-day price performance for the stock is -4.93%, and 40.88% over 30 days. With these gigs, the year-to-date price performance is -89.69%. Short interest in BioXcel Therapeutics Inc (NASDAQ:BTAI) saw shorts transact 0.32 million shares and set a 0.76 days time to cover.
The extremes give us $1 and $25 for target low and target high price respectively. As such, BTAI has been trading -1195.34% off suggested target high and 48.19% from its likely low.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 6.20% for the past 5-year period. While 2025 is set for a 73.84% return in earnings, projections for the next 5 years are at 53.72% annually.
BTAI Dividends
BioXcel Therapeutics Inc has its next earnings report out on 2025-May-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
BioXcel Therapeutics Inc insiders hold 8.65% of total outstanding shares, with institutional holders owning 11.02% of the shares at 12.06% float percentage. In total, 11.02% institutions holds shares in the company, led by ARMISTICE CAPITAL, LLC. As of 2024-06-30, the company held over 2.99 million shares (or 0.4638% of shares), all amounting to roughly $3.82 million.
The next major institution holding the largest number of shares is FMR LLC with 2.21 million shares, or about 0.3424% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $2.82 million.
